FDA Approves Oveporexton for Narcolepsy Type 1 - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Oveporexton for Narcolepsy Type 1

Directly targets the loss of orexin signaling in adults with narcolepsy type 1.

  • By

  • Kathryn Wighton

  • August 6, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Oveporexton for Narcolepsy Type 1

  • by Kathryn Wighton

  • August 6, 2026

Related Content

Factors Influencing Poor Communication Function in Children with Cerebral Palsy: A Multivariate Analysis

Sedative medications: a potentially modifiable risk factor for improving neurocognitive outcomes after critical illness in infants and children

Critically Ill Children Show Disrupted Sleep Patterns and Atypical Electroencephalograms: An Observational Cohort Study